Cohance Lifesciences Announces Acquisition of NJ Bio and Sapala, Aiming for US$1 Billion Global Revenue by 2030

Cohance Lifesciences Ltd, a technology-led Contract Research, Development & Manufacturing Organisation (CRDMO), has announced the acquisition of a controlling stake in NJ Bio, Inc. and a partnership with Sapala. These strategic moves are aimed at enhancing Cohance's capabilities in Antibody Drug Conjugates (ADCs) and oligonucleotide chemistry, respectively. The company is focused on becoming a global force in ADC/XDC innovation and leading in high-growth, high-impact therapeutic areas. The acquisitions are expected to amplify Cohance's ability to innovate, scale, and lead in these areas, reinforcing its commitment to patient-centric pharmaceutical development and sustainable value creation. Cohance aims to achieve a US$1 billion global revenue by 2030.